Skip to content

Journal of Psychiatric Research

ISSN 1879-1379, 0022-3956

99 papers in the library · 1,202 citations · publishing 1996-2026

Papers

Sort Most recent Most cited

The effects of ketamine and esketamine on functional outcomes in major depressive disorder and treatment-resistant depression: A systematic review

Journal of Psychiatric Research October 30, 2025 Isabella S Ji, Morgan C H Cheng, Kayla M Teopiz et al. 2 citations

INTRODUCTION: Functional impairment is commonly reported amongst individuals with major depressive disorder (MDD) or treatment-resistant depression (TRD). Extant evidence suggests that ketamine and esketamine, N-methyl-D-aspartate (NMDA) receptor antagonists and glutamatergic modulators, have shown efficacy in treating MDD/TRD. While symptom reduction remains central to treatment, many...

Both online and face-to-face mindfulness meditation can change cortical structure in internet gaming disorder.

Journal of Psychiatric Research October 1, 2025 Haohao Dong, Huabin Wang, Xuefeng Xu et al.

Mindfulness meditation (MM) has been shown to effectively alleviate symptoms of Internet Gaming Disorder (IGD) and improve neural functioning. However, it remains unclear whether both online and face-to-face MM can enhance cortical structure, a stable and reliable neural biomarker. This study included 100 IGD patients randomly assigned to three groups: face-to-face MM (31 participants), online...

DOI: 10.1016/j.jpsychires.2025.08.005 (opens in new tab) Full text (opens in new tab) Cortical morphology Internet gaming disorder Mindfulness meditation Structural covariance

Is ketamine safe for individuals in higher level of care treatment for eating disorders? Analysis of safety of subanesthetic ketamine in 104 patients.

Journal of Psychiatric Research August 1, 2025 Elizabeth Wassenaar, Dan V. Blalock, Alan Duffy et al. 4 citations

Eating disorders are among the most challenging and fatal mental illnesses and, due to the complication of medical instability caused by malnutrition or other disordered eating behaviors, pose unique treatment challenges for patients with co-occurring depression and mood disorders. Randomized control trials have demonstrated "rapid and robust antidepressant effects" of generic ketamine in...

DOI: 10.1016/j.jpsychires.2025.05.055 (opens in new tab) Full text (opens in new tab) Mental health research Antidepressive agents Malnutrition Mood disorders +4

Therapeutic benefit versus epistemic risk: Need for empirical research in psychedelic epistemology.

Journal of Psychiatric Research August 1, 2025 Lucas F Borkel, Jaime Rojas-Hernández, Domingo J Quintana-Hernández et al. 4 citations

This paper highlights the ethical and epistemic challenges posed by psychedelic therapy and vindicates the importance of epistemology in the clinical and psychotherapeutic setting. Despite their relative physiological and psychological safety, these substances can induce changes in the beliefs of those who use them, such as paranormal beliefs. To explain the changes in beliefs, we introduced...

Drug-related suicidal ideation in the K-12 population: a real-world pharmacovigilance study of the FDA adverse event reporting system (FAERS) database.

Journal of Psychiatric Research August 1, 2025 Yaxin Ju, Yuan Liu, Li Tan et al. 3 citations

The K-12 population refers to individuals, primarily aged 6-17, from kindergarten through 12th grade. Drug-related suicidal ideation (SI) in the K-12 population is a major concern. This study aims to identify medications linked to increased SI risk in the K-12 population using the FDA Adverse Event Reporting System (FAERS) database. We extracted cases of SI in individuals aged 6-17 years where...

Partial rescue of schizophrenia-related phenotypes in young adult Sp4 hypomorphic mice.

Journal of Psychiatric Research July 1, 2025 Joris Kamp, Megan E Sikkink, Mahalah R Buell et al.

The Schizophrenia Exome Sequencing Meta-Analysis (SCHEMA) Consortium found that truncation of one copy of the SP4 gene has an odds ratio of 9.37 (3.38-29.7) for schizophrenia (SCZ). Human SP4 gene is also one of the 69 schizophrenia-risk genes prioritized by parallel genome-wide association studies (GWAS) and one of the two schizophrenia-risk genes shared between the SCHEMA and the GWAS,...

Alexithymia and psychopathological dimensions in First-Episode Psychosis: Comparative patterns in natural cannabis versus synthetic cannabinoid users

Journal of Psychiatric Research June 19, 2025 Valerio Ricci, Ilenia di Muzio, Mancusi Gianluca et al. 2 citations

AIMS: This study aimed to investigate the differences in psychotic symptomatology, dissociative symptoms, alexithymia, and aberrant salience among three groups: non-cannabis users (NU), natural cannabis users (NC), and synthetic cannabinoid users (SCs). The study also explored the patterns of alexithymia and its associations with other psychopathological dimensions in these populations....

Adverse reactions among psychedelic users: Norwegian validation of the Challenging Experience Questionnaire

Journal of Psychiatric Research May 26, 2025 Bjørn Holmøy, Tor-Morten Kvam, Kristoffer Andreas Aamodt Andersen et al. 3 citations

Psychedelic drugs, known for their potent psychoactive effects, have gained attention for their potential therapeutic benefits in treating mental disorders. However, distressing experiences induced by psychedelics can lead to adverse long-term effects. To better assess these experiences, we aimed to provide a Norwegian translation and psychometric validation of the Challenging Experience...

Increased sensitivity to psychomotor effects of ketamine enantiomers in the Wistar-Kyoto depression model.

Journal of Psychiatric Research April 1, 2025 Kristian Elersič, Anamarija Banjac, Marko Živin et al. 3 citations

Ketamine, a fast-acting antidepressant, is a racemic mixture, composed of equal amounts of R- and S-ketamine. Preclinical studies are comparing them to better understand their role in therapeutic and undesirable effects. An important research gap is that studies do not use long clinically relevant protocols to compare the desired and undesired effects of ketamine enantiomers in modeled and...

DOI: 10.1016/j.jpsychires.2025.02.061 (opens in new tab) Full text (opens in new tab) Depressive disorder Depression mood disorder Clinical depression Ketamine ketalar +10

Associations between psychedelic-related and meditation-related variables: A longitudinal study.

Journal of Psychiatric Research March 17, 2025 Otto Simonsson, Sankalp Chaturvedi, Peter S. Hendricks et al. 2 citations

Previous research has investigated associations between psychedelic experiences and meditation practice, but knowledge gaps remain. Using a longitudinal research design with a sample of US residents between 18 and 50 years old (N = 13,012), we investigated associations between psychedelic-related and meditation-related variables. The follow-up survey was completed by 7484 respondents, of whom...

The effects of psychedelic-assisted therapy on illness and death anxiety: A systematic review and meta-analysis.

Journal of Psychiatric Research March 14, 2025 Aron Amaev, Jianmeng Song, Yasaman Kambari et al. 8 citations

Illness anxiety (IA) is characterized by worry or fear in response to living with a chronic illness or a preoccupation with having or acquiring a serious disease in conjunction with absent to mild somatic symptomatology. Death anxiety (DA) may underpin IA and is more common in individuals with life-threatening illness. Treatments for DA and IA, such as psychotherapy and antidepressant drugs,...

DOI: 10.1016/j.jpsychires.2025.03.022 (opens in new tab) Innovative therapeutic approach Profound anxieties Existential dread Mental health peace +2

Esketamine reduces the risk of postpartum depression in women undergoing cesarean section: A systematic review and meta-analysis.

Journal of Psychiatric Research March 1, 2025 Lőrinc Frivaldszky, Kincső Lőrincz, Jakub Hoferica et al. 4 citations

Postpartum depression (PPD) is a prevalent and debilitating disorder that occurs in 14% of women after giving birth. We aimed to assess the efficacy and safety of perioperative esketamine for preventing PPD in women undergoing cesarean section. We performed a systematic literature search in five medical databases - MEDLINE, Cochrane Library, Embase, Scopus, and Web of Science on the 12th of...

DOI: 10.1016/j.jpsychires.2025.02.021 (opens in new tab) Full text (opens in new tab) Postpartum depression ppd Postnatal depression Cesarean section c-section Caesarean delivery +4

Mindfulness-Based Stress Reduction Program for reducing anxiety and depression in hospital staff during a pandemic: A randomized controlled trial.

Journal of Psychiatric Research 2025 Carolina Mariño-narvaez, Borja Romero-Gonzalez, Jose A Puertas-Gonzalez et al. 7 citations

Hospital staff have experienced an increase in psychopathological symptoms such as anxiety or depression during the COVID-19 pandemic. Thus, the aims of the present research were, firstly, to study the effectiveness of the Mindfulness-Based Stress Reduction Program in reducing psychopathological symptoms in hospital staff during the COVID-19 pandemic, as well as, its effectiveness in increasing...

Effects of mindfulness-based stress reduction on neuropeptide Y plasma levels in stressed individuals.

Journal of Psychiatric Research 2025 Helle Degnbol Østergaard, Karen Johanne Pallesen, Marit Nyholm Nielsen et al.

Clinical studies have suggested that dysregulation of the neuropeptide Y (NPY) system may play a role in psychiatric disorders, including chronic stress. Meanwhile, Mindfulness Based Stress Reduction (MBSR) has shown promise for stress-related maladies. However, no studies have explored whether MBSR can change plasma NPY concentration in stressed individuals. Individuals with symptoms of...

Imagery rehearsal therapy for the treatment of nightmares in individuals with borderline personality disorder – A pilot study

Journal of Psychiatric Research December 28, 2024 Clara Sayk, Nicole Koch, Janine Stierand et al. 6 citations

Insomnia and nightmares are present in up to 45 % of individuals with borderline personality disorder (BPD) and can contribute to challenges with emotion regulation, low sleep quality, dream anxiety, increased arousal and self-control. Despite their prevalence, nightmares are usually not addressed in classical BPD treatment. Imagery rehearsal therapy (IRT) is considered first in line treatment...

DOI: 10.1016/j.jpsychires.2024.12.044 (opens in new tab) Borderline personality disorder Clinical psychology Psychotherapist Psychoanalysis

Intranasal esketamine for patients with major depressive disorder: A systematic review and meta-analysis.

Journal of Psychiatric Research December 1, 2024 Soroush Oraee, Mohammadreza Alinejadfard, Hossein Golsorkh et al. 13 citations

A large number of people worldwide grapple with Major Depressive Disorder (MDD), and a significant portion of them confront resistance to conventional antidepressant treatments. Esketamine, an innovative intervention, has garnered attention due to its rapid-acting antidepressant effects. This meta-analysis aimed to evaluate the efficacy and safety of esketamine in individuals with MDD and...

The impact of antidepressant discontinuation prior to treatment with psilocybin for treatment-resistant depression.

Journal of Psychiatric Research December 1, 2024 Lindsey Marwood, Megan Croal, Sunil Mistry et al. 9 citations

It has been suggested that the recent use and discontinuation of antidepressant drugs compromises the action of psilocybin. As evidence is only available from small or uncontrolled samples, this post hoc analysis investigated this using data from the largest, phase II, randomized controlled trial of psilocybin treatment to date. Data from 233 participants with treatment-resistant depression...

Effective action of silymarin against ketamine-induced schizophrenia in male mice: Insight into the biochemical and molecular mechanisms of action.

Journal of Psychiatric Research November 1, 2024 Benneth Ben-Azu, Aliance R Fokoua, Olajide S Annafi et al. 24 citations

Neurochemical dysregulations resulting from N-methyl-D-aspartate hypofunction (NMDA), are exacerbated by neuroimmune and oxidative stress and are known risk factors for neuropsychiatric disorders like schizophrenia-like diseases. Here, we investigate the protective and curative effects, and mechanisms of silymarin, a polyphenolic flavonoid with neuroprotective functions in preventive-reversal...

DOI: 10.1016/j.jpsychires.2024.09.003 (opens in new tab) Full text (opens in new tab) Antipsychotics Negative symptoms Neuropharmacology Psychosis +6

Increased risk of hallucinations among people with cancer: Role of loneliness, job satisfaction, sleep and a moderated-mediated model of anxiety and life satisfaction

Journal of Psychiatric Research October 4, 2024 Caroline Kamau, Bárbara Lopes 2 citations

Being diagnosed with cancer and coping with fears about potential death might trigger acute distress. Previous research found that patients with cancer are 1.85 times more at risk of developing mental illness. Whereas previous studies investigated the risk of schizophrenia, no studies have investigated the risk of individual psychotic symptoms such as hallucinations. This was an analysis of the...

Sex difference alters the behavioral and cognitive performance in a rat model of schizophrenia induced by sub-chronic ketamine.

Journal of Psychiatric Research October 1, 2024 Mohammad-Ali Samizadeh, Seyedeh-Tabassom Abdollahi-Keyvani, Hamed Fallah et al. 21 citations

Schizophrenia is a complex neuropsychiatric disorder with positive, negative, and cognitive symptoms. In rats, sub-chronic administration of ketamine is used for the induction of schizophrenia model. Increased locomotor activity is one of the most important features of psychotic-like symptoms in rodents. On the other hand, risperidone is a potent antipsychotic medication that is approved for...

Ketamine alleviates PTSD-like effect and improves hippocampal synaptic plasticity via regulation of GSK-3β/GR signaling of rats.

Journal of Psychiatric Research October 1, 2024 Zixun Wang, Xinyu Hu, Zhongyi Wang et al. 9 citations

Each year, 3-4% of the global population experiences post-traumatic stress disorder (PTSD), a chronic mental disorder with significant social and economic repercussions. Although it has been shown that ketamine can effectively alleviate PTSD symptoms in individuals, the specific mechanism of action underlying its anti-PTSD effects remains unclear. In this study, we investigated how a single,...

A preliminary investigation of the acute effects of delta-9-tetrahydrocannabinol on pain and opioid attentional bias among persons with opioid use disorder.

Journal of Psychiatric Research September 1, 2024 Noah R Wolkowicz, Mehmet Sofuoglu, Brian Pittman et al.

Attentional bias (AB) is believed to be an important factor in the development and maintenance of both opioid use disorder (OUD) and chronic pain. Cannabis and its main psychoactive constituent, delta-9-tetrahydrocannabinol (THC), produce analgesic effects via processes that are potentially relevant to AB and is commonly used by persons with OUD. This exploratory study investigated if THC...

Protocols and practices in psilocybin assisted psychotherapy for depression: A systematic review.

Journal of Psychiatric Research August 1, 2024 Noah Chisamore, Danica E. Johnson, Margery J.q. Chen et al. 21 citations

Psilocybin-assisted psychotherapy (PAP) is a promising treatment option for depression, with randomized controlled trials (RCTs) providing preliminary support for its safety and efficacy. However, there is a lack of consistency across existing treatment protocols and psychotherapeutic approaches. The objective of this review is to summarize and compare current psychotherapy methods of PAP in...

Rapid and long-lasting effects of subcutaneous esketamine on suicidality: An open-label study in patients with treatment-resistant depression.

Journal of Psychiatric Research August 1, 2024 Eduardo Igor Torquato Cardoso Lopes, Patrícia Cavalcanti-Ribeiro, Fernanda Palhano-Fontes et al. 9 citations

Therapeutics for suicide management is limited, taking weeks to work. This open-label clinical trial with 18 treatment-resistant depressive patients tested subcutaneous esketamine (8 weekly sessions) for suicidality. We noted a rapid and enduring effect of subcutaneous esketamine, lasting from one week to six months post-treatment, assessed by the Beck Inventory for Suicidality (BSI). There was...

Ketamine and electroconvulsive therapy for severe depression: A network meta-analysis of efficacy and safety.

Journal of Psychiatric Research July 1, 2024 Yecun Liu, Jiguo Yang, Yuanxiang Liu 8 citations

Ketamine, electroconvulsive therapy (ECT), and their combination are effective for treating severe depression, but few large-scale studies have compared these. We searched databases for randomized controlled trials (RCTs) using ketamine, ECT, ketamine + ECT, or placebo for severe depression. Standardized measures were efficacy outcomes. Risk of bias was assessed. Stata and ADDIS were used for...

DOI: 10.1016/j.jpsychires.2024.05.022 (opens in new tab) Full text (opens in new tab) Ketamine Electroconvulsive therapy Network meta-analysis Severe depression +5